Table IIIb-BPatient Characteristics

StudyAgeRace (%)Disease StageDisease StagePerformance StatusComorbidities or Other Prognostic Factors
Neoadjuvant Hormonal Therapy
None
Adjuvant Hormonal Therapy
Ryden et al 2005TAMCxNot reported Tumor sizeLymph node status(%)Not reported TAMCx
Med4545TAMCxTAMCxpER-/PR-3026
Rge25–5726–57Med2522Neg30260.4ER-/PR+810
(p=0.03)1+-3+5049ER+/PR-45
Rge5–752–50≥4+2024ER+/PR+5457
Unk<1<1P=0.6
Nottingham histologic grade (%)Not done42
TAMCxp
110120.6
23944
3 4542
Not Done 6 2
Knoop et al. 2001All% HER2+ in each age grpNot reported Tumor size(%)Degree of anaplasia (%)Not reported All% HER2+ in each group
<50<114<20 mm19I26ER-3432
50–59222621–50 mm56II47ER+6611
60–694518>50 mm25III15p=0.001
70–793015NR<1Other11PR-5727
80–8934Med=40 mm
Rge=0–250 mm
NR1PR+437
p=.001p=0.001
med for all=66
range for all=45–88
Metastatic Hormonal Therapy
Arpino et al. 2004Her2+Her2-Grp1Grp2Grp1Grp2Grp1Grp2ScaleGrp1Grp2Her2+Her2-
Agenot reportedInot reportedMnTnot reportednot reportedER+100%100%
<6566%57%BIIT1PR+78%96%
≥6534%43%WIIIT2PR-19%4%
HIVT3
pre16%12%AUnkT4
post84%88%ON0
N1
N2
N3
Unk
*

p<.05

From: Appendix C. Evidence Data Abstraction Tables

Cover of HER2 Testing to Manage Patients With Breast Cancer or Other Solid Tumors
HER2 Testing to Manage Patients With Breast Cancer or Other Solid Tumors.
Evidence Reports/Technology Assessments, No. 172.
Seidenfeld J, Samson DJ, Rothenberg BM, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.